Namodenoson Treatment of Advanced Pancreatic Cancer
Status:
RECRUITING
Trial end date:
2026-12-15
Target enrollment:
Participant gender:
Summary
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.